Aurinia Pharmaceuticals (AUPH)

Executive Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) is a Canadian biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, with a primary focus on nephrology. Its lead product, LUPKYNIS® (voclosporin), is FDA-approved for the treatment of adults with active lupus nephritis (LN). The company has a pipeline of 18 candidates, including voclosporin in various stages of development for indications such as dry eye syndrome and psoriasis. Aurinia's commercial execution has driven steady revenue growth, but recent setbacks include the termination of two Phase 3 trials for adolescent LN due to enrollment challenges. The company continues to explore label expansion and new indications to maximize LUPKYNIS's potential. Looking ahead, Aurinia's near-term outlook is primarily tied to the commercial performance of LUPKYNIS and potential pipeline progress. Key catalysts include the initiation of a Phase 2/3 trial for a new indication (e.g., IgA nephropathy) and potential label expansion based on real-world evidence. The company's strong cash position supports R&D efforts, but competitive pressures and patent expiration risks warrant caution. Overall, Aurinia is well-positioned in the LN market but faces execution risks in pipeline advancement.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2/3 Trial for IgA Nephropathy40% success
• 2027Supplemental NDA Submission for Label Expansion in Adolescent Lupus Nephritis20% success
• Q3 2026Q3 2026 Earnings Report with LUPKYNIS Sales Update90% success